2024-06-05 09:15:55 ET
More on Bristol-Myers Squibb
- Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84%
- Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss
- Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
- Bristol's Opdivo + Yervoy bests Lenvima, Nexavar in first-line liver cancer
- Bristol's Breyanzi demonstrates efficacy across a range of B-cell malignancies
Read the full article on Seeking Alpha
For further details see:
Bristol Myers Squibb inks clinical trial pact with I-Mab